Background: Antineutrophil cytoplasmic autoantibodies (ANCA) are associated with a spectrum of necrotizing vasculitis including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited necrotizing and crescentic glomerulonephritis. Clinical observations and in vitro and in vivo experimental evidence strongly indicate that ANCA are pathogenic. Summary: The etiology and pathogenesis of ANCA-associated vasculitis (AAV) are multifactorial, with contributions from genetic factors, environmental exposures, infections, characteristics of the innate and adaptive immune system, and the intensity and duration of the injury. Acute vascular inflammation is induced when resting neutrophils that have ANCA autoantigens sequestered in cytoplasmic granules are exposed to priming factors - for example, cytokines induced by infection or phlogogenic factors released by complement activation - that cause the release of ANCA antigens on the surface of neutrophils and in the microenvironment around the neutrophils. ANCA bind to these ANCA antigens, which activates neutrophils by Fcγ receptor engagement and F(ab′)2 binding at the neutrophil cell surface. ANCA-activated neutrophils release factors that activate the alternative complement pathway, which generates C5a, a chemoattractant for neutrophils; C5a also primes the arriving neutrophils for activation by ANCA. Activated neutrophils adhere to and penetrate vessel walls, and they release toxic oxygen radicals and destructive enzymes that cause apoptosis and necrosis of the neutrophils as well as of the adjacent vessel wall cells and matrix. Key Messages: Patients with active AAV have ongoing asynchronous onsets of countless acute lesions, with each lesion evolving through stereotypical phases within 1 or 2 weeks. Induction of remission results in termination of new waves of acute lesions and allows all lesions to progress to scarring or resolution.

Keywords:
ANCA, Antineutrophil cytoplasmic autoantibodies, Autoantibodies, Polyangiitis, Vasculitis
1.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ, van Es LA, Waldherr R, Wiik A: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.
2.
Jennette JC, Falk RJ: Small vessel vasculitis. N Engl J Med 1997;337:1512-1523.
3.
Jennette JC, Falk RJ: The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007;25(suppl 44):52-56.
4.
Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, Lesavre P, Noël LH: ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005;20:1392-1399.
5.
Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318:1651-1657.
6.
Jennette JC, Hoidal JH, Falk RJ: Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 1990;75:2263-2264.
7.
Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder-Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14:1088-1096.
8.
Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung HC, Bunch DO, McGregor JG, Hogan SL, Hu Y, Yang JJ, Berg EA, Niles J, Jennette JC, Preston GA, Falk RJ: Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012;23:545-555.
9.
Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior JBA, Jennette CE, Nachman PH, Jennette JC, Falk RJ: Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-3462.
10.
Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, et al: Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-223.
11.
Jennette JC, Falk RJ: Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. Presse Med 2013;42(pt 2):493-498.
12.
Bansal PJ, Tobin MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93:398-401.
13.
Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC: Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis 2009;54:542-545.
14.
Roth AJ, Ooi J, Hess JJ, van Timmeren MM, Berg EA, Jennette CE, McGregor JA, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ: ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value. J Clin Invest 2013;123:1773-1783.
15.
ten Holder SM, Joy MS, Falk RJ: Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002;36:130-147.
16.
Pendergraft WF 3rd, Niles JL: Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014;26:42-49.
17.
Visavachaipan N, Ong-Ajyooth L, Chanchairujuira T, Parichatikanond P, Choensuchon B: Clinical features and outcomes in patient with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment in Siriraj Hospital. J Med Assoc Thai 2010;93(suppl 1):S139-S146.
18.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-2188.
19.
Jones RB: Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 2014;128:243-249.
20.
Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-4119.
21.
Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375-383.
22.
Savage CO, Gaskin G, Pusey CD, Pearson JD: Myeloperoxidase binds to vascular endothelial cells, is recognized by ANCA and can enhance complement dependent cytotoxicity. Adv Exp Med Biol 1993;336:121-123.
23.
Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP: Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fcγ RIIa. J Immunol 1994:153:1271-1280.
24.
Ewert BH, Becker ME, Jennette JC, Falk RJ: Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. Ren Fail 1995;17:125-133.
25.
Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross-linking of Fcγ receptor IIa and Fcγ receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol 1997;159:3940-3948.
26.
Kettritz R, Jennette JC, Falk RJ: Cross-linking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997;8:386-394.
27.
Kettritz R, Schreiber A, Luft FC, Haller H: Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2001;12:37-46.
28.
Williams JM, Ben-Smith A, Hewins P, Dove SK, Hughes P, McEwan R, Wakelam MJO, Savage COS: Activation of the G heterotrimeric G protein by ANCA IgG F(ab′)2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol 2003;14:661-669.
29.
Lu X, Garfield A, Rainger GE, Savage CO, Nash GB: Mediation of endothelial cell damage by serine proteases, but not superoxide released from antineutrophil cytoplasmic antibody-stimulated neutrophils. Arthritis Rheum 2006;54:1619-1628.
30.
Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-298.
31.
van der Veen BS, Chen M, Müller R, van Timmeren MM, Petersen AH, Lee PA, Satchell SC, Mathieson PW, Saleem MA, Stegeman CA, Zwerina J, Molema G, Heeringa P: Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann Rheum Dis 2011;70:356-365.
32.
Hao J, Meng LQ, Xu PC, Chen M, Zhao MH: p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS One 2012;7:e38317.
33.
Al-Ani B: Simvastatin inhibits neutrophil degranulation induced by antineutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine phenylalanine (fMLP) peptide. Saudi Med J 2013;34:477-483.
34.
Casselman BL, Kilgore KS, Miller BF, Warren JS: Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. J Lab Clin Med 1995;126:495-502.
35.
Ralston DR, Marsh CB, Lowe MP, Wewers MD: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and Fcγ receptors. J Clin Invest 1997;100:1416-1424.
36.
Jennette JC, Falk RJ: ANCAs are also anti-monocyte cytoplasmic autoantibodies. Clin J Am Soc Nephrol 2015;10:4-6.
37.
Weidner S, Carl M, Riess R, Rupprecht HD: Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: importance of monocyte and neutrophil infiltration in tissue damage. Arthritis Rheum 2004;50:3651-3657.
38.
Zhao L, David MZ, Hyjek E, Chang A, Meehan SM: M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol 2015;10:54-62.
39.
Muller Kobold AC, Kallenberg CG, Tervaert JW: Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis 1999;58:237-245.
40.
Jennette JC, Xiao H, Falk R, Gasim AM: Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol 2011;169:211-220.
41.
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-963.
42.
Schreiber A, Xiao H, Falk RJ, Jennette JC: Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006;17:3355-3364.
43.
Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, Pusey CD: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005;106:2050-2058.
44.
Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D, Nourshargh S, Cook HT, Pusey CD: Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 2009;174:1212-1220.
45.
Pfister H, Ollert M, Fröhlich LF, Quintanilla-Martinez L, Colby TV, Specks U, Jenne DE: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004;104:1411-1418.
46.
van der Geld YM, Hellmark T, Seiga D, Heeringa P, Huitema MG, Limburg P, Kallenberg CGM: Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007;66:1679-1682.
47.
Primo VC, Marusic S, Franklin CC, Goldmann WH, Achaval CG, Smith RN, Arnaout MA, Nikolic B: Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 2010;159:327-337.
48.
Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS: Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 2012;7:e28626.
49.
Brouwer E, Huitema MG, Mulder AH, Heeringa P, van Goor H, Tervaert JW, Weening JJ, Kallenberg CG: Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994;45:1120-1131.
50.
Xiao H, Heeringa P, Liu Z, Huugen D, Hu PQ, Maeda N, Falk RJ, Jennette JC: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005;167:39-45.
51.
Tidman M, Olander R, Svalander C, Danielsson D: Patients hospitalised because of small vessel vasculitis with renal involvement in the period 1975-1995: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1998;244:133-141.
52.
Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am J Pathol 2005;167:47-58.
53.
Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64.
54.
Chen M, Xing GQ, Yu F, Liu G, Zhao MH: Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009;24:1247-1252.
55.
Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, et al: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009;29:282-291.
56.
Gou SJ, Yuan J, Chen M, Yu F, Zhao MH: Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013;83:129-137.
57.
Gou SJ, Yuan J, Wang C, Zhao MH, Chen M: Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013;8:1884-1891.
58.
Molad Y, Tovar A, Ofer-Shiber S: Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract 2014;126:67-74.
59.
Chen SF, Wang FM, Li ZY, Yu F, Zhao MH, Chen M: Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther 2015;17:129.
60.
Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25:225-231.
61.
Jennette JC, Xiao H, Hu P: Complement in ANCA-associated vasculitis. Semin Nephrol 2013;33:557-564.
62.
Lepse N, Abdulahad WH, Kallenberg CG, Heeringa P: Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev 2011;11:77-83.
63.
Free ME, Bunch DO, McGregor JA, Jones BE, Berg EA, Hogan SL, Hu Y, Preston GA, Jennette JC, Falk RJ, Su MA: Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013;65:1922-1933.
64.
Ruth AJ, Kitching AR, Kwan RY, Odobasic D, Ooi JD, Timoshanko JR, Hickey MJ, Holdsworth SR: Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J Am Soc Nephrol 2006;17:1940-1949.
65.
Ooi JD, Chang J, Hickey MJ, Borza DB, Fugger L, Holdsworth SR, Kitching AR: The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci USA 2012;109:E2615-E2624.
66.
Tan DS, Gan PY, O'Sullivan KM, Hammett MV, Summers SA, Ooi JD, Lundgren BA, Boyd RL, Scott HS, Kitching AR, Chidgey AP, Holdsworth SR: Thymic deletion and regulatory T cells prevent antimyeloperoxidase GN. J Am Soc Nephrol 2013;24:573-585.
67.
Gan PY, Tan DS, Ooi JD, Alikhan MA, Kitching AR, Holdsworth SR: Myeloperoxidase peptide-based nasal tolerance in experimental ANCA-associated GN. J Am Soc Nephrol 2015, Epub ahead of print.
68.
Jennette JC: Rapidly progressive and crescentic glomerulonephritis. Kidney Int 2003;63:1164-1177.
69.
Knight A, Sandin S, Askling J: Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 2008;58:302-307.
70.
Cotch MF, Rao JK: New insights into the epidemiology of systemic vasculitis. Curr Opin Rheumatol 1996;8:19-25.
71.
O'Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT: Wegener's granulomatosis in New Zealand: evidence for a latitude dependent incidence gradient. Intern Med J 2007;37:242-246.
72.
Mahr A, Guillevin L, Poissonnet M, Aymé S: Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:92-99.
73.
Cao Y, Schmitz JL, Yang JJ, Hogan SL, Bunch DO, Hu Y, Jennette CE, Berg EA, Arnett FC Jr, Jennette JC, Falk RJ, Preston GA: DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011;22:1161-1167.
74.
Luo H, Chen M, Yang R, Xu PC, Zhao MH: The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. Hum Immunol 2011;72:422-425.
75.
Xie G, Roshandel D, Sherva R, Monarch PA, Lu EY, Kung T, Carrington K, Zhang SS, Pulit SL, Ripke S, et al: Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013;65:2457-2468.
76.
Xiao H, Ciavatta D, Aylor DL, Hu P, de Villena FP, Falk RJ, Jennette JC: Genetically determined severity of anti-myeloperoxidase glomerulonephritis. Am J Pathol 2013;182:1219-1226.
77.
Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW: Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002;4:77-79.
78.
Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982;285:606.
79.
Kim YC, Choi YS, Alam J, Kim Y, Baek KJ, Koh J, Song YW, Chung DH, Choi Y: Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice. Immunol Res 2015, Epub ahead of print.
80.
Pendergraft WF 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC, Falk RJ: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to the autoantigen proteinase 3. Nat Med 2004;10:72-79.
81.
Yang JJ, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, Schmitz JL, Pressler BM, Jennette JC, Falk RJ, Preston GA: ANCA patients have T cells responsive to complementary PR 3 antigen. Kidney Int 2008;74:1159-1169.
82.
Preston GA, Pendergraft WF 3rd, Falk RJ: New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens 2005;14:217-222.
83.
Reynolds J, Preston GA, Pressler BM, Hewins P, Brown M, Roth A, Alderman E, Bunch D, Jennette JC, Cook HT, Falk RJ, Pusey CD: Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by ‘autoantigen complementarity'. J Autoimmun 2015;59:8-18.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.